Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

464 public trials 49 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis

NCT00883337

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Investigational Site Number 056003 Brussels, Belgium
  • Investigational Site Number 056001 Ghent, Belgium
  • Investigational Site Number 056002 Hasselt, Belgium
  • Investigational Site Number 124003 Lévis, Canada
View all 54 locations
View Trial Details
Completed

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

NCT02205489

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Investigational Site Number 056002 Bruges, Belgium
  • Investigational Site Number 056001 Brussels, Belgium
  • Investigational Site Number 250009 Dijon, France
  • Investigational Site Number 250005 Lille, France
View all 20 locations
View Trial Details
Completed

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

NCT02159573

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Cullman, Alabama, United States
  • Research Site Gilbert, Arizona, United States
  • Research Site Phoenix, Arizona, United States
View all 43 locations
View Trial Details
Completed

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

NCT01578330

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Novartis Investigative Site Ankara, Turkey, Turkey (Türkiye)
  • Novartis Investigative Site Ankara, Turkey, Turkey (Türkiye)
  • Novartis Investigative Site Bursa, Turkey, Turkey (Türkiye)
  • Novartis Investigative Site Izmir, Turkey, Turkey (Türkiye)
View Trial Details
Completed

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

NCT00220779

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Barrow Neurological Institute at St. Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • Northwest NeuroSpecialists, PLLC Tucson, Arizona, United States
  • The Mt. Sinai Medical Center, Department of Neurology New York, United States
  • SUNY Health Science Center at Stony Brook, Department of Neurology Stony Brook, New York, United States
View all 37 locations
View Trial Details
Completed

Extension Study of MT-1303

NCT01890655

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site City Name, Belgium
  • Research Site City Name, Bulgaria
  • Research Site City Name, Canada
  • Research Site City Name, Croatia
View all 17 locations
View Trial Details

Related conditions